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Abstract
Background
Clinicians, professional athletes, and recreational athletes are interested in
supplementation that up-regulates nitric oxide (NO) production in blood vessel endothelium,
increasing arterial vasodilation. Benefits from these supplements include improvements in blood
pressure, muscle hyperemia, and exercise performance. Citrulline Malate (CM) is a pre-workout
ingredient, popular for its ability to increase exercise performance and blood serum
concentrations of L-arginine, resulting in NO production. Recently, Inositol-Stabilized Arginine
Silicate (ASI, Nitrosigine) has been added to many of the most popular pre-workout blends,
following a group of studies showing ASI increases serum arginine and reduces post-workout
muscle damage. Research has yet to compare CM and ASI in-vivo using a flow-mediated
dilation (FMD) technique, a validated measure of the vascular endothelium’s NO producing
ability. Thus, the purpose of this experiment was to determine the effectiveness of ASI,
compared to CM and placebo, in up-regulating NO production in blood vessels as measured by
acute changes in vasodilation.
Participants
Healthy, normotensive, and at least moderately active male (n = 16) and female (n = 8)
young adults were recruited to participate. All participants reported no pre-workout
supplementation within two weeks of their study participation, and all participants abstained
from nicotine, caffeine, and alcohol during their participation.
Method
We utilized a double-blind, within-subjects design where participants reported for three
trials, each preceded by a 7-day washout period. Upon reporting to the research center,
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participants read and signed the informed consent document, gave a brief medical history, and
remained in an upright-seated position until their blood pressure and heart rate normalized. The
participant then reclined into a comfortable supine position in a phlebotomy chair, and his or her
arm was abducted at 70 to 90 degrees and at heart level, depending on the participant’s level of
comfort. A baseline FMD measurement was obtained followed by consumption of one clinical
dose CM (8g), ASI (1.5g), or dextrose placebo (8g); the supplementation order was randomized
controlling for potential order effects. Participants completed a brief 24-hour nutrition survey
and waited for 60 minutes. After the waiting period, FMD was repeated. We used screen capture
software to record the entire FMD procedure and conducted analyses on the videos using Quipu
Cardiac Suite software.
Results
Repeated measures analysis of variance yielded a significant supplement x time effect (p
< .001), such that CM and ASI yielded a greater change in FMD response than placebo. After
allometric scaling of the FMD values, supplement x time effect remained significant (p = .001).
Discussion
Both CM and ASI increased vascular NO production as measured by a change in FMD
and may be particularly beneficial to individuals looking to increase the potential for muscle
hyperemia during exercise. Our results support previous findings that CM and ASI increase
blood serum concentrations of arginine, and are effective at increasing vascular endothelium
nitric oxide producing capacity.
Word count: 459
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Introduction
The use of dietary supplements as ergogenic aids has become increasingly commonplace
among both recreational and competitive athletes. Supplements taken to boost the production of
nitric oxide (NO) by vascular endothelium comprise a particularly large portion of popular
ergogenic aids. Endothelial cells produce NO to increase vasodilation in response to many
potential physiologic stimuli, facilitating greater blood flow to tissues. The amino acid Larginine is the primary amino acid substrate that endothelial cells use to synthesize NO (Green et
al., 2004; Hecker et al., 1990). Previously, oral supplementation with L-arginine was the most
popular mode of increasing serum concentrations of arginine, which was thought to consequently
facilitate an increase in endothelial cell nitric oxide producing capability. In the human
cardiovascular system, nitric oxide synthase enzyme uses serum arginine in the production of
NO and L-citrulline (Palmer et al., 1988). This NO, also referred to as endothelial relaxing
factor, allows arteries to dilate when vascular endothelium is exposed to mechanical stress
(Epstein et al., 1993). Both animal model studies and double-blind studies with human
participants indicate that L-arginine supplementation can improve outcomes in cardiovascular
disease states, especially improving endothelium dependent vessel dilation in people with
atherosclerosis (Preli et al., 2002). However, ergogenic and health benefits from large, orally
administered doses of L-arginine have not been consistently demonstrated in healthy individuals
or athlete populations (Alvares et al., 2014; McConnell, 2007; Tang et al., 2011).
More recently, L-citrulline and bonded arginine silicate (ASI; Nitrosigine) have become
widely consumed in place of L-arginine, because they are more effective at increasing serum
levels of arginine and may also provide ergogenic benefits (Kalman et al., 2014; Schwedhelm et
al., 2008; Wax et al., 2016). L-citrulline is naturally produced in the cardiovascular system when
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nitric oxide synthase uses L-arginine to produce NO. Unlike dietary L-arginine, orally consumed
L-citrulline is not metabolized by the liver after ingestion, and instead forms an available amino
acid pool that can be readily converted into back to arginine via the formation of Largininosuccinic acid in the urea cycle (Hecker et al., 1990). The cellular recycling process of Lcitrulline to L-arginine plays an important role in the production NO, because when
arginosuccinate synthase, an enzyme used in the conversion of L-citrulline, is inhibited, NO
production also decreases (Flam et al., 2007). ASI, a patented supplement compound, was
engineered as a dietary intervention for atherosclerosis and bone mineral density disorders
(McCarty & Zielinski, 2002). Dietary silicon may slow the development of atherosclerosis in atrisk individuals, and given the arterial health promoting properties of arginine, the ASI
compound has potential to be doubly beneficial (Loeper et al., 1979). Research has demonstrated
that dietary ASI increases serum silicate concentrations, and more effectively increases serum
arginine than supplementing with unbound L-arginine or arginine hydrochloride (Komorowski &
Perez Ojalvo., 2016; Proctor et al., 2007).
In place of L-citrulline, many pre-workout supplements now have included a compound
form that is commonly referred to as citrulline malate (CM), and recent research suggests that
exercisers may experience different ergogenic benefits when compared to LL-citrulline alone.
Similar to supplementing with L-citrulline alone, clinical doses of CM exert some influence on
the urea cycle and the production of NO during exercise; blood serum evaluation after intense
exercise shows that CM supplementation causes an increase in urea cycle metabolite and nitrite
concentrations (Breuillard et al., 2015). Studies examining potential exercise benefits have found
the CM can increase total work capacity during high intensity resistance training (Glenn et al.
2015; Perez-Guisado & Jakeman, 2010; Wax et al., 2014). CM ergogenic benefits are not only
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limited to anaerobic exercise, because the malate portion of the CM compound may positively
influence aerobic energy production (Bendahan et al., 2002). Similar to CM, ASI also outperforms L-arginine in terms of increased exercise blood flow and decreased biomarkers of
muscle fatigue following exercise (Rood-Ojalvo et al., 2015). As reported by the manufacturer
and by the current literature, ASI doses range from 0.5 to 2.0 grams, which is a significantly
smaller dose than the typical 6.0 to 8.0 gram dose of CM. A smaller dosage could be beneficial
to individuals who have previously experienced stomach discomfort with pre-workout
supplements (Kalman et al., 2015). Research on the ergogenic effects of ASI is limited because
the supplement compound form used in this study, commonly referred to as Nitrosigine, was
only recently patented in 2002. However, benefits similar to those found with CM
supplementation (increased muscle hyperemia during exercise and decreased muscle damage
biomarkers post-exercise) have been shown in a small sample (Rood-Ojalvo et al. 2015).
Although there is increasing evidence to support the ergogenic benefits of CM and ASI,
little research has examined their effects on NO production as measured with acute changes in
vasodilation. After controlling for confounding variables such as hydration, diet, and exercise, a
change in plasma NO post-supplementation can be inferred by measuring acute changes in flow
mediated dilation using ultrasound, which is a non-invasive and reliable method of measuring
blood vessel diameter and remains a staple in clinical practice (Soga et al., 2007). Additionally,
the current literature contains insight into the effect of CM on flow-mediated dilation both during
and post-exercise, but lacks examination of acute effects of CM supplementation at rest. The
purpose of this study was to determine if an acute 8g dose of CM or a 1.5g dose of ASI causes an
increase in brachial artery diameter over baseline following flow-mediated dilation. The
participants were examined while in a rested state to emulate a pre-exercise condition, because
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CM and ASI in many pre-workout supplements are commonly consumed anywhere from 30 to
60 minutes prior to the onset of exercise. This study specifically sought to determine whether
acute CM or ASI supplementation effected the NO producing capacity of endothelium dependent
vasodilation as measured by change in flow-mediated dilation. We hypothesized that an acute
dose of CM would not cause any changes in flow-mediated dilation, because the majority of
flow-mediated dilation studies report no significant difference following supplementation. The
largest observed changes in blood flow, as a result of CM supplementation, have been
immediately post moderate to intense exercise. Studies that reported changes in participant blood
pressure have used daily CM doses for at least 2 weeks; neither of those conditions are utilized in
the procedure of this study. Thus, there is little evidence to suggest that CM will have any effect
when participants are given an acute dose and examined at rest.
Literature Review
Supplementing to Increase Serum Arginine
Interest in LL-arginine supplementation began as an intervention for cardiovascular
disease states following research that uncovered the process by which endothelial cells produce a
relaxing factor, likely nitric oxide, in response to mechanical stress via the urea cycle (Hecker et
al., 1990; Palmer et al., 1988). Increasing the efficiency and production capability of the urea
cycle can have a multitude of beneficial effects (Epstein et al., 1993). Increasing urea production
capabilities could allow the body to more efficiently reduce harmful ammonia content and better
maintain blood pH, an effect that has been substantiated in animal models and in human
participants (Callis et al., 1991; Greenstein et al., 1956; Schaefer et al., 2002). With increased
serum arginine, the urea cycle has more substrate available for nitric oxide (NO) and LLcitrulline production; L-citrulline can then be easily recycled back to LL-arginine. NO,
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previously referred to as endothelial relaxing factor, was initially of greatest interest to clinicians
who sought to provide an intervention to individuals with cardiovascular pathology. Studies have
found that increasing serum arginine through oral or intravenous administration improves
cardiovascular dynamics and serum markers of cardiovascular dysfunction (Bai et al., 2009;
Deveaux et al., 2016; Orozoco-Gutierrez et al., 2010; Thorne et al., 1998). However, oral
supplementation with LL-arginine may not be the most efficient mechanism of increasing serum
arginine. Comparison studies have found that supplementing with L-citrulline, citrulline malate
(CM), or inositol stabilized arginine silicate (ASI), more efficiently elevates serum arginine and
serum citrulline (Komorowski & Hewlings, 2019; Rood-Ojalvo et al., 2015; Schwedhelm et al.,
2008). Nutritional researchers have been particularly interested in L-citrulline because
watermelon naturally contains dense quantities. However, studies of watermelon juice and rind
have determined that an exerciser seeking a clinical dose would not be able to consume enough
watermelon to experience beneficial effects (Cutrufello et al., 2015; Rimando & Perkins-Veazie,
2005).
L-citrulline and Citrulline Malate as Ergogenic Ingredients
Clinical studies of L-citrulline have found mostly similar results to those that
administered intravenous arginine to populations with cardiovascular pathologies. Most notable
among the clinical benefits from L-citrulline supplementation are its effects on hypertension.
Two recent literature reviews and meta-analyses report that in hypertensive or pre-hypertensive
participants decreases in systolic and diastolic blood pressure are experienced with long term
CM supplementation (Mahboobi et al., 2019; Figueroa et al., 2017). L-citrulline and citrulline
malate have both grown increasingly popular in sports nutrition and in strength and conditioning
studies. In trained males, CM increases cycling time to exhaustion and repetition-based
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performance during high-intensity anaerobic exercise in workouts that target the upper body
(Perez-Guisado & Jakeman, 2010; Suzuki et al., 2016). A follow-up study with resistance-trained
males, meant to examine potential differences during high-intensity lower body exercise,
confirmed the previous finding that a large dose of CM prior to exercise increases the volume of
work performed over placebo (Wax et al., 2014). Although most of the positive ergogenic effects
have been found in trained male samples, a study with trained females found that CM
supplementation increases work capacity during both upper and lower body resistance training
(Glenn et al., 2015). The mechanism by which L-citrulline improves exercise work capacity may
relate to findings of improved lactate removal following exercise, although this finding has been
disputed (da Silva et al., 2017; Kiyici et al., 2017). Consistent with the previously mentioned
findings, current CM supplements are oriented toward athletes who perform mostly highintensity anaerobic exercise, and the majority of positive ergogenic effects have been found in
trained populations (Bailey et al., 2015). When comparing the benefits of L-citrulline and
citrulline malate, CM may have more influence over aerobic exercise, because of its malate
component. Malate may benefit aerobic metabolism via an increase in the efficiency of oxidative
ATP production, because of its intermediate role in the tricarboxylic acid cycle (Bendahan et al.,
2002). The minimum dose needed to experience a benefit varies with the administration protocol
and the outcome variable measured. In the previously mentioned studies that have found
increased work capacity, an acute dose of six to eight grams of L-citrulline was administered or a
three to six gram dose was administered daily for at least seven days. However, it is worth noting
that null results have also been found with doses as large as 12 grams (Cunniffe et al., 2016).
Inositiol-Stabilized Arginine Silicate
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Inositol-stabilized arginine silicate (ASI; Nitrosigine) has recently appeared on many preworkout supplement labels, either in combination with CM or as the exclusive NO booster. As
reported by the McCarty and Zielinski (2002), ASI was originally manufactured as a complex
meant to increase serum arginine and silicate and provide an effective intervention for
atherosclerosis and hypertension. Animal research in particular supports the theory that dietary
silicon may prevent atherosclerosis development (Loeper et al., 1979). Similar to oral Lcitrulline consumption, ASI appears to lower systolic, and to an even greater degree, diastolic
blood pressure (Sylla et al., 2018). ASI has gained a reputation in the pre-workout supplement
market as a superior form of L-arginine because of the greater efficiency and length of time for
which ASI increases serum arginine levels (Proctor et al., 2007, Komorowski & Perez Ojalvo.,
2016). Similar to CM, ASI also out-performs L-arginine in terms of increased exercise blood
flow and decreased biomarkers of muscle fatigue following exercise (Rood-Ojalvo et al., 2015).
As reported by the manufacturer and by the current literature, ASI doses range from 0.5 to 2.0
grams, which is a significantly smaller dose than the typical 6.0 to 8.0 gram dose of CM. The
most common ASI dose used in research thus far follows a 1.5g/day schedule for a period of four
or more days. Acute doses are also administered in 1.5g quantities (Komorowski et al., 2015). A
smaller dosage could be beneficial to individuals who have previously experienced
gastrointestinal discomfort with pre-workout supplements (Kalman et al., 2015). Research on the
ergogenic effects of ASI is limited because of its recent rise to popularity, but benefits similar to
those found with CM supplementation (increased muscle hyperemia during exercise and
decreased muscle damage biomarkers post-exercise) have been shown (Rood-Ojalvo et al. 2015).
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Method
Participants
Twenty-four total participants, 16 men and 8 women, were recruited to participate from a
large university in the southeastern United States. Participation in the study was open to healthy,
regularly exercising young adults between the ages of 18 and 30 years. Exclusionary criteria
were as follows: hypertension, metabolic disorders, consumption of any pre-workout type
supplements within two weeks of participating in the study, nicotine consumption in any of the
previous six months, use of any prescription medications that have the potential to influence
cardiovascular response, or use of any prescription drugs that influence the menstrual cycle.
Screening for metabolic disease, tobacco use, and prescription drug use was conducted using a
standard medical questionnaire adapted to an online survey form. Participants’ physical activity
levels were assessed using the International Physical Activity Questionnaire (IPAQ). All
participants were considered to have high levels of physical activity; they reported vigorous
exercise on more than three days per week and exceeded 1500 (MET x min / week), or reported
physical activity of at least 3000 (MET x min / week). Anthropomorphic, blood pressure, and
heart rate data are found in Table 1.
Research Design
This study used a within-subjects, double-blind research design. The order of
supplementation was randomized and coded by a researcher who was not involved in data
collection or analysis in order to control for order effects and to sufficiently blind the
experimenters. Participants were asked to complete the experimental protocol in a fasted state,
verified by self-reports, and were asked abstain from caffeine and all other dietary vitamin
supplements 24 hours prior to testing. Participants recorded their dietary habits for 24 hours
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leading up the first trial, and diet summaries were sent to participants 24 hours prior to
subsequent trials to aid them in replicating their diet as accurately as possible before the second
and third trials. The dietary habits survey was administered through a Qualtrics email link, using
the participants’ preferred emails. Each participant’s brachial artery flow-mediated dilation was
assesed twice during each trial, once before supplement ingestion, and again 60 minutes postingestion. A second survey was administered following the FMD procedure to screen for
stomach discomfort. Male participants were required to wait for a minimum of seven days
between trials to allow for a supplement washout period, and were tested around the same time
of day i.e. early morning, morning, mid-day, early afternoon, etc. Female participants reported
for supplement trials during the menstrual phase of the menstrual cycle to ensure that results
were not confounded by changes in serum estradiol, which can attenuate flow-mediated dilation
response (Hashimoto et al., 1995). Because female participants allowed for approximately 28
days between trials, no further washout period precautions were taken. Otherwise, the procedure
for female participants did not differ from the male participants.
Supplementation
Participants were randomized into six groups of equal size needed to counterbalance the
order of supplementation and control for potentially confounding order effects. Regardless of the
participant’s group designation and location of the placebo trial, all participants completed the
minimum seven-day washout period before the following trial, and the longest time between
trials was 50 days. The supplement doses administered were 8g of CM (Bulk Supplements,
Henderson, Nevada), 1.5g of ASI (Nutrition 21, Purchase, New York), or 8g of dextrose, all of
which were purchased in powder form and mixed with 12 ounces of fruit punch flavored water to
mask the differences in taste between the supplements. Eight grams of dextrose were also added
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to the CM and ASI supplement drinks to keep the caloric load identical across trials. Following
baseline FMD and subsequent supplementation, the participants remained seated for 60 minutes
to allow the supplement enough time to pass through the digestive tract, at which point plasma
arginine levels should have been elevated (Kalman et al., 2015). Placebo trials reflected the exact
procedure used during the supplement trials.
Brachial Artery Flow Mediated Dilation
Generally, flow-mediated dilation procedures were determined using recommendations
from the Harris et al. (2010) tutorial on FMD assessment. All FMD measurements and AUC
calculations were completed using Quipu Cardiac Suite software to analyze a 60fps 1040 x 720p
live captured video of the ultrasound monitor during the entire 10-minute FMD procedure. Upon
reporting for trials, participants assumed a supine position in a reclining phlebotomy chair with
his or her left arm abducted from 70 to 90 degrees and placed palm up on an adjustable arm rest.
Blood pressure and heart rate were recorded from the participant’s right arm every 5 minutes
until he or she maintained stable cardiovascular values. The experimenter then measured,
marked, and recorded cuff and transducer landmarks on the participant’s left arm with a surgical
marker to ensure that the ultrasound transducer and occlusion cuff were placed in the same
location for each trial. The rapid inflation occlusion cuff (E20 and AG101 rapid cuff inflator,
Hokanson, Bellevue, WA) was placed beginning 2 cm distal from the antecubital fold, and a
10MHz ultrasound transducer (LOGIQ e, GE Healthcare, Chicago, IL, USA) was placed
beginning at least 5 cm proximal and no more than 10 cm proximal from the antecubital fold.
Dual mode Doppler ultrasound was used to simultaneously record blood flow velocity, which
would later be used in calculations of maximum shear rate, and shear rate area under the curve to
maximum (AUC). After maintaining a stable image of the brachial artery, in which both arterial
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walls were clearly visible, two minutes were allowed to elapse to provide a sufficient amount of
time for the calculation of an average baseline diameter. Following the two-minute baseline
period, the occlusion cuff was rapidly inflated to 250 mmHG for five minutes. After the fiveminute occlusion phase, the cuff was rapidly deflated and changes in artery diameter and blood
flow velocity were monitored for the following three minutes. Identical procedures were used for
the baseline and post-supplementation FMD measurements.
Analysis of Flow-Mediated Dilation
An experimenter who was blinded to the supplement ID codes and the trial numbers of
the videos individually analyzed each FMD procedure video recording using Quipu FMD Studio
software (QUIPU, Pisa, Italy). By identifying the walls of the artery and calculating the average
of several brachial artery diameter measurements in real time, the software was able to provide
an accurate measure of arterial diameter for every second of video. Baseline diameters (DBase)
reported in this study are averages of the brachial artery diameter during the entire 120 second
pre-occlusion phase, whereas maximum diameter (Dpeak) is the largest recorded diameter within
the 180 seconds following the immediate release of the occlusion cuff. The FMD percentage
(FMD%) was calculated using the following equation: (Dpeak (mm) / DBase (mm)) x 100. Similar
to diameter, the FMD Studio software also calculated an average shear rate for every second of
video. Shear rate was determined from the equation: (blood flow velocity (cm / sec) / diameter
(cm)) for which the values are expressed in units of sec-1, and shear rate AUC to maximum was
calculated by taking the first integral of the shear rate curve from cuff release to maximum
diameter.
Statistical Analyses
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A total of (n = 15) mean and (n = 6) women completed all three supplement trials.
Because, a limited number of women were able to complete the study, a 2 (sex) x 2 (time) x 3
(supplement) ANOVA was used to determine sex differences in supplement response. There was
no significant interaction with participant sex, so data were compiled and analyzed as one sample
for the remainder of the statistical analyses. A 2 (time) x 3 (supplement) repeated measures
ANOVA was used to test for significant differences in FMD%, Dbase, Dpeak, maximum shear rate,
and shear rate AUC to maximum variables.
Examinations of the relationship between FMD baseline diameter (Dbase) and FMD%
have found that there is a significant negative relationship between the two variables, which can
unintentionally bias the interpretation of the study (Atkinson & Batterham et al., 2013). In the
present study, an examination of the relationship between Dbase and FMD% yielded a much
weaker negative relationship (Figure 5), however corrective analyses were still conducted for
comparison purposes. In line with the statistical analysis procedure used by Atkinson (2014), the
natural logarithm was calculated for Dbase and Dpeak, and the aggregated valued were compiled
into a predictive regression to determine the exponent of change (see Figure 6). Corrected FMD
% was obtained using the equation ((LnDpeak / LnDbase0.94)-1) x 100 for each FMD procedure.
Additionally, because some studies have found that habitual protein consumption can effect
serum L-arginine concentrations, a 1 x 3 ANOVA was used to check for the potential confound
of both protein consumption between trials.
Because the negative correlational relationship between Dbase and FMD% was not as
strong in the present study compared to population scaled FMD studies, further controls were
used to ensure that potential changes in the FMD stimulus as measured by maximum shear rate
and shear rate AUC did not emerge as confounding variables in the study. Linear regression
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models, in which FMD% was the dependent variable and Dbase, maximum shear rate, and shear
rate AUC were predictor variables for all six FMD groups were used to test for significant
trends. If any of the linear models should be able to significantly predict FMD%, another
ANOVA would be employed using the predicted FMD% values from the regression equation.
Results
A summary of the means, standard deviations, and ANOVA results for the FMD data are
found in Table 2. For the unscaled FMD% values, there was a significant supplement x time
effect, F = 11.64, p < .001. Post-hoc analysis showed that CM and ASI supplementation resulted
in significantly higher changes in FMD% than placebo, but there was no significant difference
between the two supplements. These findings were unchanged after allometric scaling, F =
10.61, p < .001. CM increased change in FMD% from baseline by an average of 2.44, and ASI
increased change in FMD% from baseline by 2.48. Graphical plots of FMD% and corrected
FMD% change from pre-supplementation to post-supplementation are found in Figure 3 and
Figure 4, respectively. Statistical analysis found no significant interaction of supplement x time
for baseline diameter, maximum shear rate, and shear rate AUC to maximum. There was no
significant difference in protein consumption in the 24-hour period before each trial F = 0.485, p
= .51.
Results from the linear regression models and subsequent ANOVA test indicate that
FMD stimulus was not a confounding factor in the previously listed results. The post-supplement
placebo trial was the only linear regression model to significantly predict FMD%, p = .01,
although the pre-supplement placebo trial was approaching significance, p = .07. An ANOVA of
the regression-predicted values directly reflects the findings from the uncorrected and
allometrically scaled FMD% values; there was a significant supplement x time effect, F = 11.88,
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p = .001, where CM and ASI supplementation resulted in a positive FMD% change compared to
placebo, with no significant difference between the two. Graphical regression plots for all six
groups and an aggregate plot are found in Figure 7 through Figure 13.
Discussion
The purpose of this study was to determine whether acute CM or ASI supplementation
effected the NO producing capacity of endothelium dependent vasodilation as measured by
change in flow-mediated dilation. While there are several studies examining the effect of CM on
endothelium dependent vasodilation, results have thus far been inconclusive compared to the
observed ergogenic effects on high intensity exercise. Meanwhile, the present study may be one
of the first to examine the acute effects of ASI supplementation on endothelium dependent
vasodilation as measured by FMD. Results from this study indicate that both 8g CM and 1.5g
ASI, consumed in a flavored drink 60 minutes prior to testing, increase vascular endothelium
relaxing factor production in response to FMD. Although CM and ASI increase serum arginine
through slightly different mechanisms, both appear to be equally effective at increasing
endothelium response to shear stress. By scaling the data to control for the bias introduced by
baseline diameter variation, we can safely conclude that the observed changes were not unduly
influenced by statistical flaws. Additionally, using linear regression models to predict FMD%
from DBase, shear ratemax, and shear rateAUC ensures that variance in the FMD stimulus did not
predict the changes in FMD% between the supplements. Although, there is some evidence to
suggest that correcting for shear rate may not be necessary when using allometrically scaled
FMD% values (Atkinson, 2014).
It is difficult to precisely interpret the results from this study with respect to findings
from previous research into CM supplement effects on FMD. Research has firmly established
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that CM and ASI are both effective at increasing serum L-arginine levels following both acute
and continuous supplementation, and that increase is also associated with other improvements in
markers of cardiovascular function (Bailey et al., 2015; Figueroa et al., 2015; Kalman et al.,
2015; Komorowski et al., 2015). Increasing serum arginine also improves markers of
cardiovascular function and improving cardiovascular dynamics in studies of pathology in both
humans and animals (Giannesini et al., 2009; Orozco-Gutierrez et al., 2010; Proctor et al., 2007).
However, several studies that sought to increase serum arginine and subsequently test for
changes in FMD, have failed to find significant differences (Alvares et al., 2014; Figueroa et al.,
2017; Gates et al., 2007; Schwedhelm et al., 2008). While significant changes in FMD% may not
be the norm in supplement research, a relationship between ADMA, a nitric oxide pathway
inhibitor, arginine and FMD may exist. Specifically, increases in the serum arginine/ADMA
ratio trend toward an increase in FMD% (Alvares et al., 2014; Baum et al., 2016; Gates et al.,
2007; Haberka et al., 2009). Unfortunately, because no blood samples were analyzed in this
study, no further conclusions can be drawn about the arginine/ADMA ratio and its relation to
FMD. Additionally, differences in baseline serum arginine may explain a portion of the
variability in FMD results among L-arginine and L-citrulline studies. When baseline arginine
and FMD% are low, whether because of a lack in dietary protein or cardiovascular pathology,
supplementing to increase serum arginine improves FMD response and other cardiovascular
markers (Bai et al., 2009; Deveaux et al., 2016). Participants with differing cardiovascular
disease risk factors, in which differing serum arginine levels are observed, also respond
differently to increases in serum arginine, and thus experience differing FMD% improvements
(Thorne et al., 1998). Although baseline serum arginine levels were not tested in this study,
baseline arginine levels were likely consistent with population norms for the following reasons:
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average protein consumption was above the minimum 0.8 g/kg bodyweight needed to maintain
normal serum levels, all participants reported high levels of physical activity, and none of the
participants met criteria for metabolic or cardiovascular disorders (Zieve, 1986).
Given the large number of variables that have the potential to influence endothelial
function, sample homogeneity is likely an essential factor in determining the presence of an
effect, especially given the small sample sizes in most supplement studies (Preli et al., 2002).
The sample recruited for the present study was almost identical in age, and all reported very high
levels of physical activity, both factors are crucially important in terms of observed FMD
response. Consequently, the supplement effects observed in this study may be limited to highly
trained young adults. Further investigation, specifically a comparison study of younger and older
athletes will be necessary to verify this possibility.
Results from this study support a somewhat novel finding that acute supplementation
with CM and ASI can improve endothelial-dependent vasodilation in trained young adults. Prior
to this study, there was no comparison of CM and ASI effects using FMD. This study supports
previous research findings that ASI may be a beneficial pre-workout supplement, and that a 1.5g
dose of ASI may be equally as effective at increasing endothelial response as a much larger 8g
dose of CM.
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Tables and Figures
Table 1.
Sample characteristics
N

Height (cm)

Weight (kg)

Systolic BP

Diastolic BP

Male

15

181.7 ± 6.2

78.3 ± 16.5

125.6 ± 11.6

74.9 ± 10.5

Female

6

163.3 ± 3.5

61.8 ± 8.1

111.7 ± 11.4

71.7 ± 9.1
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Table 2.

Means, standard deviations, and 2 x 3 repeated measures ANOVA results for all FMD relevant
variables
PreSupplementation

60-minutes Post
Supplemetation

Citrulline
Malate

3.84 ± 0.61

3.79 ± 0.62

Nitrosigine

3.83 ± 0.48

3.78 ± 0.53

Placebo
Citrulline
Malate

3.74 ± 0.54

3.80 ± 0.52

4.12 ± 0.63

4.15 ± 0.64

Nitrosigine

4.14 ± 0.49

4.18 ± 0.56

Placebo
Citrulline
Malate

4.03 ± 0.55

4.09 ± 0.52

7.16 ± 2.44

9.60 ± 2.72

Nitrosigine

8.00 ± 3.14

10.48 ± 2.64

Placebo
Citrulline
Malate

8.04 ± 2.90

7.85 ± 2.82

7.03 ± 1.82

8.79 ± 2.01

Nitrosigine

7.32 ± 2.01

9.18 ± 1.80

Placebo
Citrulline
Malate

7.72 ± 2.17
167377.25 ±
179635.56
222580.81 ±
197033.56
317124.68 ±
205705.21

7.63 ± 2.07
278367.58 ±
219709.37
264273.34 ±
196650.11
308761.67 ±
224332.36

761.47 ± 314.66

777.34 ± 256.65

793.56 ± 401.52

775.71 ± 287.35

908.64 ± 490.64

910.30 ± 367.76

Supplement

Pre-occlusion
Diameter (mm)

Post-occlusion
Diameter (mm)

FMD %

Corrected FMD %

Hyperemic Shear
Rate to Maximum
AUC (∫ sec-1)

Nitrosigine

Placebo
Citrulline
Maximum Shear Rate Malate
(sec-1)
Nitrosigine
Placebo

ANOVA

F = 0.834, p =
.434

F = 8.18, p =
.003

F = 11.634, p
< .001

F = 10.61, p <
.001

F = 1.33, p =
.27

F = 0.04, p =
.91
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Figure 1.
Box and whisker plot of the uncorrected FMD% change scores for citrulline malate, dextrose,
and Nitrosigine. X indicates the mean, and the horizontal line within the box indicates the
median
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Figure 2.
Box and whisker plot of the FMD% change scores for citrulline malate, dextrose, and
Nitrosigine after allometric scaling. X indicates the mean, and the horizontal line within the box
indicates the median
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Figure 3.
Line plot indicating the slope of change from pre-supplementation to post-supplementation for
uncorrected FMD%

Uncorrected Mean ΔFMD%
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Nitrosigine

11

FMD%

10
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7

6

Pre-supplement

Post-supplement
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Figure 4.
Line plot indicating the slope of change from pre-supplementation to post-supplementation for
allometrically scaled FMD%

Allometrically Scaled ΔFMD%
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FMD%

9
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8
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7
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Figure 5.
Negative correlation relationship between baseline diameter and FMD%
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Figure 6.
Linear relationship between baseline diameter and peak diameter that produces the exponent
used in allometric scaling
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CITRULLINE MALATE AND NITROSIGINE
Figure 7.
Aggregate plot of linear regression adjusted FMD% values
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CITRULLINE MALATE AND NITROSIGINE
Figure 8.
Plot of linear regression adjusted FMD% values
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CITRULLINE MALATE AND NITROSIGINE
Figure 9.
Plot of linear regression adjusted FMD% values
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CITRULLINE MALATE AND NITROSIGINE
Figure 10.
Plot of linear regression adjusted FMD% values
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CITRULLINE MALATE AND NITROSIGINE
Figure 11.
Plot of linear regression adjusted FMD% values
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CITRULLINE MALATE AND NITROSIGINE
Figure 12.
Plot of linear regression adjusted FMD% values
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CITRULLINE MALATE AND NITROSIGINE
Figure 13.
Plot of linear regression adjusted FMD% values
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